Peptomyc Email Format
Research ServicesCatalonia, Spain11-50 Employees
Peptomyc is a clinical-stage biotechnology company based in Barcelona, Spain, focused on creating new mini-protein therapeutics that target the MYC oncoprotein, a central driver in cancer. The company builds on two decades of Dr. Soucek’s Omomyc research, translating this work into cell-penetrating peptides intended to inhibit MYC activity in cancer cells. Founded in December 2014, Peptomyc operates in the research services space and develops protein and peptide therapeutics for oncology. In January 2025, the company announced that its lead candidate, OMO-103, would enter a Phase 2 trial in pediatric and adult patients with advanced osteosarcoma. This ongoing clinical program reflects Peptomyc's focus on advancing MYC-targeting therapeutics through clinical development.